New malaria vaccine trial could stop recurrent fever in its tracks

NCT ID NCT07373301

First seen Jan 31, 2026 · Last updated May 10, 2026 · Updated 17 times

Summary

This study tests an experimental vaccine called PvCS/Montanide ISA-51 to see if it can safely prevent malaria caused by the P. vivax parasite. About 72 healthy adults aged 18-50 will receive three shots over four months, then be exposed to infected mosquitoes under medical supervision. The goal is to find out if the vaccine protects against infection and how well the body's immune system responds.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MALARIA PREVENTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Malaria Vaccine and Drug Development Center (MVDC)

    Cali, Valle del Cauca Department, 61000, Colombia

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.